Leap Therapeutics Files 8-K with Financial Updates
Ticker: CYPH · Form: 8-K · Filed: May 13, 2024 · CIK: 1509745
| Field | Detail |
|---|---|
| Company | Leap Therapeutics, INC. (CYPH) |
| Form Type | 8-K |
| Filed Date | May 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, operations, sec-filing
TL;DR
Leap Therapeutics dropped an 8-K on 5/13 with financial statements - check it out.
AI Summary
On May 13, 2024, Leap Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, providing an update on the company's performance. Leap Therapeutics, Inc. is incorporated in Delaware and is part of the Pharmaceutical Preparations industry.
Why It Matters
This 8-K filing provides investors with crucial, up-to-date financial information and operational details for Leap Therapeutics, Inc., enabling informed investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report of financial condition and results of operations, not indicating any immediate material adverse events.
Key Players & Entities
- Leap Therapeutics, Inc. (company) — Registrant
- May 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 (address) — Principal executive offices
- 27-4412575 (tax_id) — IRS Employer Identification No.
- 001-37990 (commission_file_number) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Leap Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as to file Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 13, 2024.
In which state is Leap Therapeutics, Inc. incorporated?
Leap Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Leap Therapeutics, Inc.?
The business address of Leap Therapeutics, Inc. is 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141.
What is the IRS Employer Identification Number for Leap Therapeutics, Inc.?
The IRS Employer Identification Number for Leap Therapeutics, Inc. is 27-4412575.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-05-13 07:10:27
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 LPTX Nasdaq Capital Market Indicate
Filing Documents
- tm2414104d1_8k.htm (8-K) — 27KB
- tm2414104d1_ex99-1.htm (EX-99.1) — 86KB
- tm2414104d1_ex99-1img01.jpg (GRAPHIC) — 10KB
- 0001104659-24-060199.txt ( ) — 304KB
- lptx-20240513.xsd (EX-101.SCH) — 3KB
- lptx-20240513_lab.xml (EX-101.LAB) — 33KB
- lptx-20240513_pre.xml (EX-101.PRE) — 22KB
- tm2414104d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On May 13, 2024, Leap Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024. The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation by reference language in such filing, unless expressly incorporated by specific reference to such filing. The information in this Current Report on Form 8-K, including the information set forth under this Item 2.02 and the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of Leap Therapeutics, Inc. dated May 13, 2024. 104 Cover Page Interactive Data File. (Embedded within the Inline XBRL document.) - 2 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEAP THERAPEUTICS, INC. Dated: May 13, 2024 By: /s/ Douglas E. Onsi Name: Douglas E. Onsi Title: Chief Executive Officer and President